**Supplementary file**

**Table S1**: Compliance of the observational (Cross-sectional) studies in the present review with STROBE-M checklist

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.1 | Study design mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 1.2 | Background explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1.3 | Objective mentioned. yes=1, no=0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1.4 | Participant selection explained. yes=1, no=0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1.5 | Methods written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1.6 | Results stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 1.7 | Conclusions mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| 2.1 | Overview of known information. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 | Recent pertinent references used. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2.3 | Gaps in current knowledge addressed. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3.1 | Populations specified. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3.2 | Exposures stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3.3 | Expected outcomes mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3.4 | Parameters to be estimated mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4.1 | Study design explicitely stated.yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 4.2 | Cohort population | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | explained. yes=1, no=0 | | | | | | | | | | | | | | | | |
| 4.3 | Institutional Review Board / Ethics committee permission mentioned. Yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| 4.4 | Informed consent taken from participants. Yes=1, no=0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| 5.1 | Study setting mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5.2 | Study location written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5.3 | Relevant dates mentioned (recruitment, exposure, follow-up, data collection). Yes=1, no=0 | 4 | 2 | 1 | 2 | 1 | 2 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,1 | Eligibility criteria stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6,2 | Sources and methods of selection of participants mentioned. yes=2, only source or method = 1, no=0 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| 7.1 | Outcome variable/s is/are defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7.2 | Exposures defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 7.3 | Predictors defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 7.4 | Potential Confounders defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.5 | Effect Modifiers defined? yes=1, no=0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 7.6 | Diagnostic Criteria defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8.1 | For each variable of interest sources of data given. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8.2 | For each variable of interest methods of assessment (measurement) mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |  | 1 | 1 |
| 8.3 | For each variable of interest comparability of assessment methods described (If there is more than one group). yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 | Efforts to address potential sources of bias described. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 10.1 | Known prevalence of variable from literature stated. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| 10.2 | Required significance mentioned. yes=1, no=0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 10.3 | Required power mentioned. yes=1, no=0 | NA | 0 | NA | 1 | NA | 0 | NA | NA | NA | 0 | 0 | 0 | 0 | 0 | NA | NA |
| 11.1 | Explained how quantitative variables were handled in the analyses. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11.2 | Described which groupings were chosen. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.3 | Described why specific grouping were chosen. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 12.1 | Statistical methods, including those used to control for confounding explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 12.2 | Methods used to examine subgroups and interactions explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 12.3 | Method to handle missing data addressed. yes=1, no=0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| 12.4 | For cross-sectional study, described analytical methods taking account of | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. 2015 | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et al.2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | sampling strategy. yes=1, no=0 | | | | | | | | | | | | | | | | |
| 12.5 | Sensitivity analyses described. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 13.1 | Numbers of eligible Individuals reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 13.2 | Number of individuals Included in the Study reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 13.4 | Number of individuals analyzed reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 13.5 | Give Reasons for Non-participation at each stage. yes=1, no=0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.6 | Recruitment and follow-up flow diagram presented. yes=1, no=0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| 14.1 | Characteristics (eg, Demographic, Clinical, Social) of study participants written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| 14.2 | Information on potential confounders written. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| 14.3 | Number of participants with missing data for each variable of interest indicated. yes=1, no=0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| 15 | Cross-sectional Study: Numbers of outcome | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | events or summary measures reported. yes=1, no=0 | | | | | | | | | | | | | | | | |
| 16.1 | Given unadjusted estimates with precision (confidence interval). yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 16.2 | Given confounder-adjusted estimates (confidence interval). yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
| 16.3 | Described which confounders were adjusted for and why they were Included. yes=1, no=0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
| 16.4 | Reported category | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | boundaries when continuous variables were categorized. yes=1, no=0 | | | | | | | | | | | | | | | | |
| 16.5 | Reported estimates of relative risk into absolute risk for a meaningful time period. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 17 | Reported other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses. yes=1, no=0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| 18 | Summarized key results with reference to study objectives. yes=1, no=0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. 2015 | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et al.2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.1 | Discussed study limitations. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 19.2 | Discussed direction and magnitude of potential bias. yes=1, no=0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| 20.1 | Presented a cautious overall interpretation considering objectives, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 20.2 | Presented a cautious overall interpretation considering limitations, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 20.3 | Presented a cautious overall interpretation considering multiplicity of analyses, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. 2015 | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et al.2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.4 | Presented a cautious overall interpretation considering results from Similar Studies, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 20.5 | Presented a cautious overall interpretation considering and other Relevant Evidence yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 21 | Discussed the generalizability (external validity) of the study results. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 22.1 | Given the source of funding. yes=1, no=0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| 22.2 | Given the role of the funders for the present | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |

| Sr. no. | Scoring scale | Maximum possible Score | Sumon et al. 2023 | Win et al. | Islam et.al. | Huda et al. | Sk et al. | Tigga, et al. 2015 | Deshmukh, et al. 2013 | Yeleswarapu, et al. 2012 | Adhikari et al. 2019 | Budhathoki et al. 2019 | Brauner-Otto, et al. | Khaliq et al.2021 | Khan et al. | Shinsugi, et al.2019 | Galgamuwa, et al.2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | study. yes=1, no=0 | | | | | | | | | | | | | | | | |
| 22.3 | Stated author's and co-authors contributions. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| 22.4 | Given a statement on data available online. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| 22.5 | Given a statement on competing interests. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| | Total | **77** | 62 | 61 | 63 | 51 | 63 | 49 | 48 | 47 | 63 | 61 | 55 | 67 | 59 | 61 | 56 |
| | percentage compliance | 100 | 80.51 | 79.22 | 81.81 | 66.23 | 81.81 | 63.63 | 62.33 | 61.03 | 81.81 | 79.22 | 71.42 | 87.01 | 76.62 | 79.22 | 72.72 |

**Table S2**: Compliance of the observational (Case-control) studies in the present review with STROBE-M checklist

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 1.1 | Study design mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 1.2 | Background explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 |
| 1.3 | Objective mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 1.4 | Participant selection explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 1.5 | Methods written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 1.6 | Results stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 1.7 | Conclusions mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 2.1 | Overview of known information. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 2.2 | Recent pertinent references used. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 2.3 | Gaps in current knowledge addressed. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 3.1 | Populations specified. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 3.2 | Exposures stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 3.3 | Expected outcomes mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 3.4 | Parameters to be estimated mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 4.1 | Study design explicitly stated. Yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 4.2 | Cohort population explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 4.3 | Follow up time period stated. yes=1, no=0 | 1 | 0 | 1 | 1 | 1 |

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 4.4 | Institutional Review Board / Ethics committee permission mentioned. Yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 4.5 | Informed consent taken from participants. Yes=1, no=0 | 1 | 1 | 1 | 0 | 1 |
| 5.1 | Study setting mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 5.2 | Study location written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 5.3 | Relevant dates mentioned (recruitment, exposure, follow-up, data collection). All 4 dates mentioned=4, few dates mentioned (1 to 3) = 1 to 3, no=0 | 2 | 0 | 2 | 2 | 1 |
| 6,1 Case control | Eligibility criteria stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 6,2 Case Control | Sources and methods of case ascertainment and control selection written. yes=2, only source or method = 1, no=0 | 2 | 2 | 2 | 2 | 1 |
| 6,3 Case control | Rationale for the choice of cases and controls stated. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 6,4 Case control | For matched studies give matching criteria. yes=1, no=0 | 1 | 1 | 0 | 1 | 1 |
| 6,5 Case control | For matched studies give number of controls per case. yes=1, no=0 | 1 | 1 | 0 | 1 | 1 |
| 7.1 | Outcome variable/s is/are defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 7.2 | Exposures defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 7.3 | Predictors defined? yes=1, no=0 | 1 | 0 | 1 | 0 | 1 |

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 7.4 | Potential Confounders defined? yes=1, no=0 | 1 | 0 | 0 | 0 | 1 |
| 7.5 | Effect Modifiers defined? yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 7.6 | Diagnostic Criteria defined? yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 8.1 | For each variable of interest sources of data given. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 8.2 | For each variable of interest methods of Assessment (measurement) mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 8.3 | For each variable of interest Comparability of assessment methods described (If there is more than one group). yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 9 | Efforts to address potential sources of bias described. yes=1, no=0 | 1 | 0 | 0 | 1 | 0 |
| 10.1 | Known prevalence of variable from literature stated. yes=1, no=0 | 1 | 1 | 0 | 0 | 0 |
| 10.2 | Required significance mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 10.3 | Required power mentioned. yes=1, no=0 | 1 | 1 | 1 | 1 | 0 |
| 11.1 | Explained how quantitative variables were handled in the analyses. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 11.2 | Described which groupings were chosen. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 11.3 | Described Why specific grouping were chosen. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 12.1 | Statistical methods, including those used to control for confounding explained. yes=1, no=0 | 1 | 0 | 1 | 0 | 1 |
| 12.2 | Methods used to examine subgroups and interactions explained. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 12.3 | Method to handle missing data addressed. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 12.4 | For Case-control study, explained how matching of cases and controls was addressed. yes=1, no=0 | 1 | 1 | 0 | 1 | 1 |
| 12.5 | Sensitivity analyses described. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 13.1 | 13.1 Numbers of eligible Individuals reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 13.2 | 13.2 Number of individuals Included in the Study reported. yes=1, no=0, | 1 | 1 | 1 | 1 | 1 |
| 13.3 | Number of individuals completing follow-up reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 13.4 | Number of individuals analyzed reported. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 13.5 | Give Reasons for Non-participation at each stage. yes=1, no=0 | 1 | 1 | 0 | 1 | 0 |
| 13.6 | Recruitment and follow-up flow diagram presented. yes=1, no=0 | 1 | 1 | 0 | 0 | 0 |
| 14.1 | Characteristics (eg, Demographic, Clinical, Social) of study participants written. yes=1, no=0 | 1 | 1 | 0 | 0 | 1 |
| 14.2 | Information on exposures and potential confounders written. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 14.3 | Number of participants with missing data for each variable of interest indicated. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 15 | Case-control Study: Numbers in each exposure category, or summary measures of exposure reported. yes=1, no=0 | 1 | 1 | 1 | 0 | 1 |

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 16.1 | Given unadjusted estimates with precision (confidence interval). yes=1, no=0, NA | 1 | 1 | 1 | 1 | 1 |
| 16.2 | Given confounder-adjusted estimates (confidence interval). yes=1, no=0 | 1 | 1 | 1 | 0 | 1 |
| 16.3 | Described which confounders were adjusted for and why they were Included. yes=1, no=0 | 1 | 0 | 0 | 0 | 1 |
| 16.4 | Reported category boundaries when continuous variables were categorized. | 1 | 1 | 1 | 1 | 1 |
| 16.5 | Reported estimates of relative risk into absolute risk for a meaningful time period. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 17 | Reported other analyses done—eg, analyses of subgroups and interactions, and sensitivity analyses. yes=1, no=0 | 1 | 0 | 0 | 1 | 0 |
| 18 | Summarized key results with reference to study objectives. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 19.1 | Discussed study limitations. yes=1, no=0 | 1 | 1 | 1 | 0 | 0 |
| 19.2 | Discussed direction and magnitude of potential bias. yes=1, no=0 | 2 | 0 | 1 | 1 | 0 |
| 20.1 | Presented a cautious overall interpretation considering objectives, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 20.2 | Presented a cautious overall interpretation considering limitations, yes=1, no=0 | 1 | 1 | 1 | 0 | 0 |
| 20.3 | Presented a cautious overall interpretation considering multiplicity of Analyses, yes=1, no=0 | 1 | 0 | 1 | 0 | 0 |
| 20.4 | Presented a cautious overall interpretation considering results from Similar Studies, yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |

| Sr.no. | Scoring scale | Maximum possible Score | Sigdel et al. 2020 | Hossain et al. 2020 | Ambadekar et al. 2017 | Iftikhar et al. 2017 |
|---|---|---|---|---|---|---|
| 20.5 | Presented a cautious overall interpretation considering and other Relevant Evidence yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 21 | Discussed the generalizability (external validity) of the study results. yes=1, no=0 | 1 | 1 | 0 | 0 | 0 |
| 22.1 | Given the source of funding. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| 22.2 | Given the role of the funders for the present study. yes=1, no=0 | 1 | 0 | 0 | 0 | 0 |
| 22.3 | Stated author's and co-authors contributions. yes=1, no=0 | 1 | 1 | 1 | 0 | 1 |
| 22.4 | Given a statement on data available online. yes=1, no=0 | 1 | 1 | 0 | 0 | 0 |
| 22.5 | Given a statement on competing interests. yes=1, no=0 | 1 | 1 | 1 | 1 | 1 |
| | Total | **81** | **63** | **61** | **58** | **59** |
| | percentage compliance | 100 | 77.77 | 75.3 | 71.6 | 72.83 |